Kretzler L, Große S, Wiedemann S, et al. - Among patients suffering from mitral valve regurgitation (MR) managed by MitraClip implantation, this inquiry was performed to assess alterations in pulmonary function, pulmonary pressure and diffusing capacity of the lung. This study involved 43 patients (19 females and 24 males with an average age of 78.0 ± 6.6 years) who were able to perform pulmonary function testing prior to as well as 6 weeks following MitraClip implantation. A successful reduction of MR severity, evident in the vast majority of patients, was conferred by MR treatment with the MitraClip system. Consecutively, pulmonary pressure decreased, however, there were no obvious alterations in left ventricular ejection fraction. Follow-up revealed no change in lung function tests. However, a significant improvement in DLCO (diffusing capacity of the lung for carbon monoxide), which was consequent to MitraClip procedure, was seen in a subgroup of patients with severe preexisting deterioration of DLCO.